Investors who own more than 5% of a class must file a Schedule 13D or 13G. The latest filing for each security since 12/18/2024, newest first.
| Issuer | % of Class | Filed |
|---|---|---|
|
enGene Therapeutics Inc.
13G/A
ENGN · 29286X101
|
0.8% |
8/12/2026
Event 6/30/2026
|
|
Context Therapeutics Inc.
13G/A
CNTX · 21077P108
|
3.2% |
8/12/2026
Event 6/30/2026
|
|
Aktis Oncology, Inc.
13G
AKTS · 01021M104
|
5.9% |
5/14/2026
Event 3/31/2026
|
|
Repare Therapeutics Inc.
13G/A
RPTX · 760273102
|
0% |
5/14/2026
Event 3/31/2026
|
|
Larimar Therapeutics, Inc.
13G/A
LRMR · 517125100
|
10.0% |
5/14/2026
Event 3/31/2026
|
|
ImageneBio, Inc.
13G/A
IMA · 45175G207
|
8.5% |
5/14/2026
Event 3/31/2026
|
|
Finance of America Companies Inc.
13G
FOA · 31738L206
|
9.5% |
2/12/2026
Event 12/31/2025
|
|
FS Credit Opportunities Corp.
13G/A
30290YAD3
|
0% |
2/12/2026
Event 12/31/2025
|
|
Nuveen Churchill Direct Lending Corp.
13G/A
NCDL · 67090S108
|
4.3% |
2/12/2026
Event 12/31/2025
|
|
Biomea Fusion, Inc.
13G
BMEA · 09077A106
|
5.9% |
2/12/2026
Event 12/31/2025
|
|
Katapult Holdings, Inc.
13D/A
KPLT · 485859201
|
0.5% |
11/5/2025
Event 11/3/2025
|
|
Marker Therapeutics, Inc.
13G/A
MRKR · 57055L206
|
10.0% |
5/15/2025
Event 3/31/2025
|
|
Sagimet Biosciences Inc.
13G/A
SGMT · 786700104
|
4.3% |
2/14/2025
Event 12/31/2024
|
|
AEON Biopharma, Inc.
13G/A
AEON · 00791X100
|
3.8% |
2/14/2025
Event 12/31/2024
|
|
Tourmaline Bio, Inc.
13G/A
TRML · 89157D105
|
4.2% |
2/14/2025
Event 12/31/2024
|
|
Generation Asia I Acquisition Ltd
13G/A
GAQ · G38258102
|
0% |
2/14/2025
Event 12/31/2024
|
|
Lument Finance Trust, Inc.
13G
LFTPRA · 55025L207
|
8.3% |
2/14/2025
Event 12/31/2024
|
|
Arbor Realty Trust Inc
13G
ABRPRE · 038923868
|
6.3% |
2/14/2025
Event 12/31/2024
|